Eiger Bio­Phar­ma­ceu­ti­cals to fo­cus on GLP-1 can­di­date, cut work­force by 25%

Eiger Bio­Phar­ma­ceu­ti­cals said it’s now fo­cused on de­vel­op­ing a GLP-1 an­tag­o­nist amid a re­view of its busi­ness that in­cludes lay­ing off 25% of its em­ploy­ees and cut­ting R&D spend­ing on a liv­er dis­ease treat­ment.

The Cal­i­for­nia biotech re­vealed the piv­ot Thurs­day, telling in­vestors that it will now fo­cus on avex­i­tide in pa­tients with post-bariatric hy­po­glycemia, a rare com­pli­ca­tion of weight loss surg­eries such as gas­tric by­pass, ac­cord­ing to David Apelian, who has for­mal­ly been named CEO af­ter serv­ing in an in­ter­im role.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER